Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real‐world analysis

Background Nivolumab was approved for the treatment of advanced gastric cancer in 2017 in Japan. The aim of this study was to assess the impact of nivolumab in a real‐world clinical setting. Methods This single‐institutional retrospective study included patients with advanced gastric or esophagogast...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2024-06, Vol.13 (12), p.e7401-n/a
Main Authors: Kadono, Toru, Iwasa, Satoru, Hirose, Toshiharu, Hirano, Hidekazu, Okita, Natsuko, Shoji, Hirokazu, Takashima, Atsuo, Kato, Ken
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Cellular biology
Chemotherapy
Clinical medicine
Epidermal growth factor
Esophagogastric Junction - pathology
Female
Gastric cancer
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Japan
Liver
Lymphatic system
Male
Medical prognosis
Metastasis
Middle Aged
Mortality
Nivolumab - therapeutic use
Oncology
overall survival
Patients
prognostic factors
real‐world data
Retrospective Studies
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Survival
time to treatment‐discontinuation
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Nivolumab was approved for the treatment of advanced gastric cancer in 2017 in Japan. The aim of this study was to assess the impact of nivolumab in a real‐world clinical setting. Methods This single‐institutional retrospective study included patients with advanced gastric or esophagogastric junction adenocarcinoma and a history of first‐line chemotherapy with platinum‐based doublet or triplet regimens between 2010 and 2020. To assess the impact of nivolumab on survival, the patients were divided based on the year of nivolumab approval into a pre‐2017 (2010–2016) group and a post‐2017 (2017–2020) group. Results From a total of 1918 patients, 1093 were excluded. There were 533 patients in the pre‐2017 group and 292 in the post‐2017 group. Immune checkpoint inhibitors were used significantly more often in the post‐2017 group than in the pre‐2017 group (8.6% vs. 47.9%). Median overall survival was significantly longer in the post‐2017 group (16.9 vs. 13.9 months; hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.63–0.90; p 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.7401